子宫内膜癌微创手术中术中肿瘤溢出及其对复发风险的影响
该病例对照研究纳入2017至2022年间接受腹腔镜或机器人辅助子宫切除术且最终病理为子宫内膜癌的患者,比较复发组与无复发对照组。复发组20%(17/86)存在术中肿瘤溢出,对照组为4%(7/172);校正肿瘤大小、深肌层浸润和辅助治疗后,术中肿瘤溢出者复发风险约为无溢出者的5.63倍(aOR 5.63,95%CI 1.52-20.86)。作者认为术中肿瘤溢出与复发相关,需进一步研究是否调整辅助治疗或手术技术。
要点
- 子宫内膜癌微创手术中,术中肿瘤溢出者复发风险约为无溢出者的5.63倍(aOR 5.63,95%CI 1.52-20.86)。
- 复发组术中肿瘤溢出比例为20%(17/86),无复发对照组为4%(7/172)。
- 作者认为术中肿瘤溢出与复发相关,需进一步研究是否调整辅助治疗或手术技术。
核心结论
- 在子宫内膜癌患者中,本研究发现术中肿瘤溢出与癌症复发存在关联。
- 这些发现需进一步研究以确定是否应调整辅助治疗或手术技术以改善结局。
研究设计与样本
- 病例对照研究,纳入2017至2022年间接受腹腔镜或机器人辅助子宫切除术且最终病理为子宫内膜癌的患者。
- 比较有后续复发者(病例)与无复发者(对照),查阅电子病历获取人口学、术中及病理资料和复发状态。
- 共1057例患者接受子宫内膜癌微创手术,约8%(n=86)出现复发,选取172例作为对照。
主要发现
- 复发组中20%(17/86)存在术中肿瘤溢出,无复发对照组中为4%(7/172)。
- 校正肿瘤大小、深肌层浸润和辅助治疗后,有术中肿瘤溢出者复发比值约为无溢出者的5.63倍(aOR 5.63,95%CI 1.52-20.86)。
关键数值与推荐
- 术中肿瘤溢出的定义包括:使用举宫器导致子宫穿孔、阴道切开或标本取出后出现宫外肿瘤、未封闭标本暴露于腹膜腔和/或病理或手术报告注明标本碎裂。
- 条件logistic回归用于确定癌症复发与术中肿瘤溢出关联的比值比。
- 校正因素为>50%肌层浸润、肿瘤大小和辅助治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The prognostic impact of intra-operative tumor spillage (ITS) during minimally invasive surgery (MIS) for endometrial cancer (EC) is not well studied. The objective of this study was to determine if there is an association between ITS and EC recurrence. METHODS: We performed a case-control study of patients with a laparoscopic or robot-assisted hysterectomy with EC on final pathology between 2017 and 2022 and compared those with (case) and without (control) a subsequent EC recurrence. Electronic medical records were reviewed for demographic, intra-operative and pathologic details, and recurrence status. ITS was defined as uterine perforation with a manipulator, presence of extra-uterine tumor after colpotomy or specimen delivery, exposure of uncontained specimen into peritoneum, and/or pathology/operative reports noting specimen fragmentation. Conditional logistic regression was used to determine odds ratios for the association of cancer recurrence with ITS. We adjusted for >50% myoinvasion, tumor size, and adjuvant treatment. RESULTS: 1057 patients underwent MIS for EC. Approximately 8% (n = 86) developed recurrent cancer and 172 patients were selected as controls. Twenty percent of recurrent cases (17/86) had ITS compared with 4% of nonrecurrent controls (7/172). When adjusted for tumor size, deep myoinvasion, and adjuvant treatment, patients with ITS had a 5.6 times increased odds (aOR 5.63, 95% CI 1.52-20.86) of recurrence compared to patients without ITS. CONCLUSIONS: In patients with EC, we found an association between ITS and cancer recurrence. These findings warrant further investigation to determine if adjuvant therapy or surgical technique should be altered to improve outcomes.
引用
- Saini A, Suh L, Gao J, et al. Intra-operative tumor spillage in minimally invasive surgery for endometrial cancer and its impact on recurrence risk. Gynecol Oncol. 2023. PMID: 37356313. doi:10.1016/j.ygyno.2023.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。